NCT02321475View on ClinicalTrials.gov

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Cognitive Disorders
Interventions
DRUG

EGb761®

Trial Locations (2)

117152

Russian National Research Medical University, Moscow

119435

First Moscow State Medical University, Moscow

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY